Lazard Asset Management LLC Acquires 27,287 Shares of Incyte Corporation $INCY

Lazard Asset Management LLC boosted its holdings in shares of Incyte Corporation (NASDAQ:INCY) by 14.2% during the 1st quarter, HoldingsChannel.com reports. The institutional investor owned 219,881 shares of the biopharmaceutical company’s stock after acquiring an additional 27,287 shares during the period. Lazard Asset Management LLC’s holdings in Incyte were worth $20,695,000 as of its most recent SEC filing.

Other large investors have also recently made changes to their positions in the company. Elyxium Wealth LLC acquired a new position in shares of Incyte during the fourth quarter valued at about $28,000. Smithfield Trust Co raised its holdings in shares of Incyte by 135.0% in the 4th quarter. Smithfield Trust Co now owns 282 shares of the biopharmaceutical company’s stock worth $28,000 after acquiring an additional 162 shares during the last quarter. MUFG Securities EMEA plc acquired a new stake in shares of Incyte in the 2nd quarter worth about $32,000. CYBER HORNET ETFs LLC bought a new position in Incyte in the 2nd quarter valued at about $33,000. Finally, Leonteq Securities AG bought a new position in Incyte in the 4th quarter valued at about $35,000. 96.97% of the stock is owned by institutional investors.

Incyte Stock Up 9.3%

Incyte stock opened at $129.93 on Wednesday. Incyte Corporation has a fifty-two week low of $71.00 and a fifty-two week high of $132.60. The stock has a market cap of $25.96 billion, a PE ratio of 18.35, a price-to-earnings-growth ratio of 1.03 and a beta of 0.76. The firm’s 50-day simple moving average is $107.99 and its 200 day simple moving average is $101.86. The company has a debt-to-equity ratio of 0.01, a quick ratio of 3.60 and a current ratio of 3.68.

Incyte (NASDAQ:INCY) last posted its quarterly earnings data on Tuesday, July 28th. The biopharmaceutical company reported $3.09 EPS for the quarter, beating the consensus estimate of $2.20 by $0.89. The firm had revenue of $1.67 billion during the quarter, compared to analyst estimates of $1.50 billion. Incyte had a net margin of 26.71% and a return on equity of 26.66%. The company’s revenue for the quarter was up 37.7% on a year-over-year basis. During the same quarter last year, the business posted $1.57 EPS. Research analysts predict that Incyte Corporation will post 6.9 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of analysts have commented on INCY shares. BMO Capital Markets boosted their price objective on Incyte from $94.00 to $112.00 and gave the stock a “market perform” rating in a report on Monday, July 13th. Sanford C. Bernstein started coverage on Incyte in a report on Thursday, May 21st. They issued a “market perform” rating and a $99.00 target price on the stock. Stifel Nicolaus set a $145.00 target price on Incyte in a report on Tuesday. JPMorgan Chase & Co. lifted their target price on Incyte from $105.00 to $110.00 and gave the company a “neutral” rating in a research report on Thursday, July 23rd. Finally, Citigroup reiterated a “market perform” rating on shares of Incyte in a report on Wednesday, July 15th. Eight investment analysts have rated the stock with a Buy rating and fourteen have given a Hold rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Hold” and an average target price of $112.85.

Trending Headlines about Incyte

Here are the key news stories impacting Incyte this week:

• Positive Sentiment: Quarterly results exceeded expectations. Incyte reported $1.67 billion in second-quarter revenue, up 37.7% year over year and above the $1.50 billion consensus estimate. Adjusted EPS of $3.09 also surpassed the $2.20 consensus, while GAAP net income reached $585.6 million. Incyte earnings results
• Positive Sentiment: Management raised full-year 2026 guidance. Total net sales guidance increased to $5.13 billion-$5.26 billion from $4.77 billion-$4.94 billion. The improved outlook reflects stronger expectations for Opzelura and the Hematology and Oncology portfolio. INCY Q2 earnings and guidance
• Positive Sentiment: Product growth broadened beyond Jakafi. Jakafi and Jakafi XR sales rose 7% to $817 million, while Opzelura sales surged 173% to $450 million and Hematology and Oncology sales increased 69% to $222 million. Management said growth from Jakafi, Opzelura, Niktimvo, Monjuvi and Zynyz supports a more diversified commercial business. Incyte is no longer a one-drug story
• Positive Sentiment: A CMS-related Opzelura agreement boosted the outlook. Incyte expects the agreement to contribute approximately $300 million-$310 million to 2026 Opzelura sales, including a $246 million one-time, non-cash benefit recognized in the quarter. The company also expects 10 clinical readouts, including four registrational trials, during the second half of 2026. Incyte raises sales outlook
• Neutral Sentiment: Incyte discontinued an early-stage JAK inhibitor program to focus resources on next-generation pipeline candidates. This may improve strategic focus but removes one development opportunity. Incyte JAK inhibitor decision
• Negative Sentiment: Some risks remain after the rally. A Seeking Alpha contributor downgraded the stock from Buy to Hold following its substantial advance, and the median analyst price target of $105 is below recent trading levels. In addition, reported insider activity showed sales but no purchases over the past six months. Incyte rating downgrade

Incyte Company Profile

Incyte Corporation is a Wilmington, Delaware–based biopharmaceutical company focused on the discovery, development and commercialization of novel therapies in oncology and inflammation. Since its founding in 2002, Incyte has grown from a small research organization into a global enterprise, advancing a portfolio of internally developed and partnered assets. The company’s research and development efforts center on small-molecule drugs and biologics that modulate critical signaling pathways implicated in cancer, autoimmune disorders and rare diseases.

The company’s flagship product is Jakafi® (ruxolitinib), a Janus kinase (JAK) inhibitor approved for the treatment of myelofibrosis and polycythemia vera.